DeCure for Microcephalic osteodysplastic primordial dwarfism type II
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephalic osteodysplastic primordial dwarfism type II — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephalic osteodysplastic primordial dwarfism type II maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephalic osteodysplastic primordial dwarfism type ii is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The three abstracts describe only the natural history and genetics of microcephalic osteodysplastic primordial dwarfism (MOPD), not any treatment or drug. In 2012, three additional patients with MOPD type I were reported, all carrying mutations in the RNU4ATAC gene. Two patients from one family had novel heterozygous mutations (g.66G>C and g.124G>A) in the 3′ stem-loop; a third patient from another family had a homozygous g.55G>A mutation in the 5′ stem-loop. These patients had a milder phenotype than previously described: they lacked severe developmental delay and neurological symptoms, though they still showed the known spectrum of clinical features. The abstract from 2000 describes two children of consanguineous Arabic parents with growth retardation, microcephalus, facial anomalies, and osteodysplastic deformities including hip dysplasia. One child had decreased growth hormone levels. Neither showed signs of mental retardation, which the authors used to distinguish them from Seckel syndrome and classify them within the heterogeneous MOPD group. The 2014 report describes a single neonate with MOPD type I and an unusual association of subpulmonic ventricular septal defect and a dorsal interhemispheric brain cyst. The authors note that fewer than 30 cases of MOPD type I had been reported worldwide.
No drug, no intervention, and no clinical trial data appear in any of these abstracts. The 2000 paper explicitly states that the exact pathogenesis remains unknown and that the most probable cause is autosomal recessive inheritance. The 2012 paper expands the known mutational and phenotypic spectrum but offers no therapeutic direction. The 2014 paper is a single case report of an anatomical association.
What is missing is any molecular target for a drug, any preclinical model in which a compound could be tested, any funding for natural history studies that might identify modifiable pathways, and any trial design that could measure a treatment effect in a disorder with fewer than 100 reported cases worldwide. Without patient stratification by specific RNU4ATAC mutation and without a quantitative outcome measure that captures the relevant aspects of growth or brain development, no drug-repurposing hypothesis can be evaluated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2012 · 32 citations
Expanding the phenotypic and mutational spectrum in microcephalic osteodysplastic primordial dwarfism type I
AbstractMutations in the RNU4ATAC gene cause microcephalic osteodysplastic primordial dwarfism type I. It encodes U4atac, a small nuclear RNA that is a component of the minor spliceosome. Six distinct mutations in 30 patients diagnosed as microcephalic osteodysplastic primordial dwarfism type I have been described. We report on three additional patients from two unrelated families presenting with a milder phenotype of microcephalic osteodysplastic primordial dwarfism type I and metopic synostosis. Patient 1 had two novel heterozygous mutations in the 3' prime stem-loop, g.66G > C and g.124G > A while Patients 2 and 3 had a homozygous mutation g.55G > A in the 5' prime stem-loop. Although they manifested the known spectrum of clinical features of microcephalic osteodysplastic primordial dwarfism type I, they lacked evidence of severe developmental delay and neurological symptoms. These findings expand the mutational and phenotypic spectrum of this syndrome.
Zeitschrift für Orthopädie und ihre Grenzgebiete · 2000 · 2 citations
Differentialdiagnostische Überlegungen zum mikrozephalen Zwergwuchs
AbstractPURPOSE: While the rare Seckel-Syndrome is defined by clear criteria, clinical and radiologic findings for microcephalic osteodysplastic primordial dwarfism (MOPD) make an exact diagnosis and classification difficult. By comparing our patients to previously described cases of MOPD we evaluate the hypothesis that this disorder has a greater heterogeneity than has been believed up until now. Furthermore the differential diagnosis of the MOPD-complex is discussed. RESULTS: Two cases that show typical growth retardation, microcephalus and facial anomalies as well as osteodysplastic deformities including hip dysplasia are presented. The parents of both children are consanguineous and of Arabic race. In one of the children growth hormone levels were noticeably decreased. In discrepancy to the Seckel-syndrome both children showed no signs of mental retardation, therefore the classification into the heterogeneous group of microcephalic osteodysplastic primordial dwarfism (MOPD) is the most likely diagnosis. CONCLUSION: It is suggested that microcephalic osteodysplastic primordial dwarfism (MOPD) has a greater clinical and radiological expression than has been assumed up until now. Whether our results are merely a variant or suggest a new subtype of the MOPD can only be resolved by further cases. The exact pathogenesis of the disease currently remains unknown but the most probable cause is an autosomal recessive inheritance.
Journal of Clinical Neonatology · 2014 · 1 citations
An unusual association of microcephalic osteodysplastic primordial dwarfism type I with cardiac and brain anomalies
AbstractLess than 100 cases of primordial dwarfism have been reported worldwide out of which Microcephalic osteodysplastic primordial dwarfism type I comprise about <30 cases. We report a rare case of extreme growth failure in a neonate with primordial dwarfism of antenatal onset due to Microcephalic osteodysplastic primordial dwarfism type I. Our case is also unique in being associated with hitertho unreported association of subpulmonic ventricular septal defect and a dorsal interhemispheric cyst in the brain.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
